Day: April 1, 2018

Today announced the display of interim results from the first Phase I/II trial of samalizumab.

Data shown today at the 52nd American Culture of Hematology Annual Getting together with and Exposition in Orlando indicate that samalizumab was well tolerated at all dosages studied, exhibited a dose-dependent biological and pharmacokinetic response, and exhibited initial proof anti-tumor activity. The early-stage clinical findings presented today are consistent with the predicted system of action of samalizumab and support further study of this novel antibody, stated Stephen Squinto, Ph.D., Executive Vice Head and President of Analysis and Development at Alexion. We anticipate completing this trial, analyzing the final data set, and additional investigating samalizumab as a forward thinking treatment for patients with additional cancers. Read More